(Q46036804)

18 December 2017

title

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. (English)

1 reference

18 December 2017

0 references

0 references

1 reference

1 reference

Mark C Genovese

1

1 reference

18 December 2017

Roy M Fleischmann

2

1 reference

18 December 2017

Maria Greenwald

3

1 reference

18 December 2017

Julie Satterwhite

4

1 reference

18 December 2017

Melissa Veenhuizen

5

1 reference

18 December 2017

Li Xie

6

1 reference

18 December 2017

Pierre-Yves Berclaz

7

1 reference

18 December 2017

Stephen Myers

8

1 reference

18 December 2017

Olivier Benichou

9

1 reference

18 December 2017

language of work or name

English

0 references

publication date

25 December 2012

1 reference

18 December 2017

Annals of the Rheumatic Diseases

published in

1 reference

18 December 2017

volume

72

1 reference

18 December 2017

issue

9

1 reference

18 December 2017

page(s)

1461-1468

1 reference

18 December 2017

Guidelines for the management of rheumatoid arthritis: 2002 Update

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Targeting BAFF in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202775

10.1136/ANNRHEUMDIS-2012-202775

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017